Deal focused on HCV

Deal focused on HCV

Oct 15th 2012 - Edison Investment Research today published a report on Bhp Billiton entitled "Deal Focused On HCV". In summary, the report says: Benitec's acquisition of its US-based technology licensee, Tacere Therapeutics, allows the Australian RNAi specialist to bring in-house a Phase I-ready drug candidate for Hepatitis C virus infection.

Start the conversation, or Read more at Stockopedia.

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.